244 related articles for article (PubMed ID: 26053587)
21. Renal medullary carcinoma, a rare cause of haematuria in sickle cell trait.
Patel K; Livni N; Macdonald D
Br J Haematol; 2006 Jan; 132(1):1. PubMed ID: 16371012
[No Abstract] [Full Text] [Related]
22. ALK rearrangement in sickle cell trait-associated renal medullary carcinoma.
Mariño-Enríquez A; Ou WB; Weldon CB; Fletcher JA; Pérez-Atayde AR
Genes Chromosomes Cancer; 2011 Mar; 50(3):146-53. PubMed ID: 21213368
[TBL] [Abstract][Full Text] [Related]
23. Prolonged survival of a patient with sickle cell trait and metastatic renal medullary carcinoma.
Pirich LM; Chou P; Walterhouse DO
J Pediatr Hematol Oncol; 1999; 21(1):67-9. PubMed ID: 10029817
[TBL] [Abstract][Full Text] [Related]
24. Renal medullary carcinomas: histopathologic phenotype associated with diverse genotypes.
Gatalica Z; Lilleberg SL; Monzon FA; Koul MS; Bridge JA; Knezetic J; Legendre B; Sharma P; McCue PA
Hum Pathol; 2011 Dec; 42(12):1979-88. PubMed ID: 21733559
[TBL] [Abstract][Full Text] [Related]
25. Renal medullary carcinoma: a potential sickle cell nephropathy of children and adolescents.
Wesche WA; Wilimas J; Khare V; Parham DM
Pediatr Pathol Lab Med; 1998; 18(1):97-113. PubMed ID: 9566287
[TBL] [Abstract][Full Text] [Related]
26. Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments.
Wei D; Yang Y; Ricketts CJ; Vocke CD; Ball MW; Sourbier C; Wangsa D; Wangsa D; Guha R; Zhang X; Wilson K; Chen L; Meltzer PS; Ried T; Thomas CJ; Merino MJ; Linehan WM
Genes Chromosomes Cancer; 2020 Aug; 59(8):472-483. PubMed ID: 32259323
[TBL] [Abstract][Full Text] [Related]
27. Haplotype-resolved germline and somatic alterations in renal medullary carcinomas.
Tan KT; Kim H; Carrot-Zhang J; Zhang Y; Kim WJ; Kugener G; Wala JA; Howard TP; Chi YY; Beroukhim R; Li H; Ha G; Alper SL; Perlman EJ; Mullen EA; Hahn WC; Meyerson M; Hong AL
Genome Med; 2021 Jul; 13(1):114. PubMed ID: 34261517
[TBL] [Abstract][Full Text] [Related]
28. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy.
Schaeffer EM; Guzzo TJ; Furge KA; Netto G; Westphal M; Dykema K; Yang X; Zhou M; Teh BT; Pavlovich CP
BJU Int; 2010 Jul; 106(1):62-5. PubMed ID: 20002663
[TBL] [Abstract][Full Text] [Related]
29. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.
Msaouel P; Hong AL; Mullen EA; Atkins MB; Walker CL; Lee CH; Carden MA; Genovese G; Linehan WM; Rao P; Merino MJ; Grodman H; Dome JS; Fernandez CV; Geller JI; Apolo AB; Daw NC; Hodges HC; Moxey-Mims M; Wei D; Bottaro DP; Staehler M; Karam JA; Rathmell WK; Tannir NM
Clin Genitourin Cancer; 2019 Feb; 17(1):1-6. PubMed ID: 30287223
[TBL] [Abstract][Full Text] [Related]
30. Renal medullary carcinoma. Case report and review of the literature.
Leitão VA; da Silva W; Ferreira U; Denardi F; Billis A; Rodrigues Netto N
Urol Int; 2006; 77(2):184-6. PubMed ID: 16888429
[TBL] [Abstract][Full Text] [Related]
31. Renal Medullary Carcinoma.
Elliott A; Bruner E
Arch Pathol Lab Med; 2019 Dec; 143(12):1556-1561. PubMed ID: 30855171
[TBL] [Abstract][Full Text] [Related]
32. Renal medullary carcinoma: the Bronx experience.
Hakimi AA; Koi PT; Milhoua PM; Blitman NM; Li M; Hugec V; Dutcher JP; Ghavamian R
Urology; 2007 Nov; 70(5):878-82. PubMed ID: 18068443
[TBL] [Abstract][Full Text] [Related]
33. Complications associated with sickle cell trait: a brief narrative review.
Tsaras G; Owusu-Ansah A; Boateng FO; Amoateng-Adjepong Y
Am J Med; 2009 Jun; 122(6):507-12. PubMed ID: 19393983
[TBL] [Abstract][Full Text] [Related]
34. Renal Medullary Carcinoma: The Kidney Cancer That Affects Individuals With Sickle Cell Trait and Disease.
Alvarez OA
J Oncol Pract; 2017 Jul; 13(7):424-425. PubMed ID: 28697316
[No Abstract] [Full Text] [Related]
35. Renal medullary carcinoma: a report of 2 cases and review of the literature.
Dimashkieh H; Choe J; Mutema G
Arch Pathol Lab Med; 2003 Mar; 127(3):e135-8. PubMed ID: 12653601
[TBL] [Abstract][Full Text] [Related]
36. Renal Medullary Carcinoma With Metastasis to the Temporal Fossa and Orbit.
Chumdermpadetsuk R; Tooley AA; Godfrey KJ; Krawitz B; Feldstein N; Kazim M
Ophthalmic Plast Reconstr Surg; 2019; 35(6):e149-e151. PubMed ID: 31574041
[TBL] [Abstract][Full Text] [Related]
37. SMARCB1/INI1 inactivation in renal medullary carcinoma.
Calderaro J; Moroch J; Pierron G; Pedeutour F; Grison C; Maillé P; Soyeux P; de la Taille A; Couturier J; Vieillefond A; Rousselet MC; Delattre O; Allory Y
Histopathology; 2012 Sep; 61(3):428-35. PubMed ID: 22686875
[TBL] [Abstract][Full Text] [Related]
38. Renal medullary carcinoma.
Baig MA; Lin YS; Rasheed J; Mittman N
J Natl Med Assoc; 2006 Jul; 98(7):1171-4. PubMed ID: 16895289
[TBL] [Abstract][Full Text] [Related]
39. Renal Medullary Carcinoma: a Report of the Current Literature.
Blas L; Roberti J; Petroni J; Reniero L; Cicora F
Curr Urol Rep; 2019 Jan; 20(1):4. PubMed ID: 30656488
[TBL] [Abstract][Full Text] [Related]
40. Renal medullary carcinoma: a nearly fatal malignancy specifically affecting patients with a so-called benign condition.
Goenaga-Vázquez Y; Colón G; Barrios N; Correa M
CEN Case Rep; 2018 May; 7(1):121-126. PubMed ID: 29396817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
